Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy

AIDS

Volumn 15, Issue 2, 2001, Pages 195-200

  Suarez, S ^a   Baril, L ^a   Stankoff, B ^a   Khellaf, M ^a   Dubois, B ^a   Lubetzki, C ^a   Bricaire, F ^a   Hauw, J J ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

AIDS dementia complex; Cognitive impairment; HAART; HIV; Memory; Neuropsychological tests; Protease inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AMNESIA; ARTICLE; COGNITIVE DEFECT; DISEASE DURATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; MORTALITY; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RECALL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COGNITION; COGNITION DISORDERS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0035951476     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101260-00008     Document Type: Article

References (40)

1. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type-1 (HIV-1) infection: Reports of a Working Group of the American Academy of Neurology AIDS Task Force
2. Changes in neuropsychological performance of AIDS-related complex patients who progress to AIDS
3. Decline in working memory associated with HIV infection
4. Cognitive performance after progression to AIDS: A longitudinal study from the Multicenter AIDS Cohort Study
5. Dementia in AIDS patients: Incidence and risk factors
6. Neuropsychological performance in symptomatic and asymptomatic HIV infection
7. Similar subcortical pattern of cognitive impairment in AIDS patients with and without dementia
8. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 lymphocyte cell counts of 200 per cubic millimeter or less
9. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
10. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men
11. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy
12. HIV-1-related neurological disease incidence changes in the era of highly active antiretroviral therapy
13. HIV-1-associated cognitive/motor complex: Absence of neuronal loss in the cerebral neocortex
14. Clinical-neuropathologic correlation in HIV-associated dementia, Neurology
15. Regional brain atrophy in HIV-1 infection: Association with specific neuropsychologucal test performance
16. Neuronal density in the superior frontal and temporal gyri does not correlate with the degree of human immunodeficiency virus-associated dementia
17. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients
18. Brain atrophy in HIV infection is more strongly associated with CDC clinical stage than with cognitive impairment
19. Progressive cerebral volume loss in human immunodeficiency virus infection
20. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex
21. Plasma and cerebrospinal fluid human immunodeficiency virus type-1 (HIV-1) RNA levels in HIV-related cognitive impairment
22. 'Mini-Mental State'. A practical method for grading the cognitive state of patients for the clinician
23. Mental status examination for organic mental syndrome in the elderly patient
24. Genuine memory deficits in dementia
25. Validity of the Trail Making test as indicator of organic brain damage
26. Purdue Pegboard as a predictor of the presence and laterality of cerebral lesions
27. Normative data for the Purdue Pegboard on a sample of adult candidates for vocational rehabilitation
28. A new depression scale designed to be sensitive to change
29. Longitudinal analysis for discrete and continuous outcomes
30. Neurological outcomes in late HIV infection: Adverse impact of neurological impairment on survival and protective effect of antiviral therapy
31. Information processing and antiretroviral therapy in HIV-1 infection
32. Human immunodeficiency virus-associated dementia: Review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy
33. Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function
34. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment
35. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia
36. Clinical and spectroscopic improvement in HIV-associated cognitive impairment
37. Detection of subclinical motor dysfunctions in early symptomatic HIV infection with topographical EEG
38. Slowed information processing in HIV-1 disease. The Multicenter AIDS Cohort Study (MACS)
39. Motor skill impairment in SIV-infected rhesus macaques with rapidely and slowly progressing disease